ECSP066683A - Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes - Google Patents
Vacuna para mejorar el crecimiento, a base de epítopes neutralizantesInfo
- Publication number
- ECSP066683A ECSP066683A EC2006006683A ECSP066683A ECSP066683A EC SP066683 A ECSP066683 A EC SP066683A EC 2006006683 A EC2006006683 A EC 2006006683A EC SP066683 A ECSP066683 A EC SP066683A EC SP066683 A ECSP066683 A EC SP066683A
- Authority
- EC
- Ecuador
- Prior art keywords
- peptides
- new
- epithopes
- vaccine
- neutralizing
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000003472 neutralizing effect Effects 0.000 title 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53371903P | 2003-12-31 | 2003-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066683A true ECSP066683A (es) | 2006-10-25 |
Family
ID=34748944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006683A ECSP066683A (es) | 2003-12-31 | 2006-06-29 | Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7371726B2 (enExample) |
| EP (1) | EP1699820A2 (enExample) |
| JP (2) | JP2007535912A (enExample) |
| KR (1) | KR20060120229A (enExample) |
| CN (1) | CN1902221A (enExample) |
| AR (1) | AR047345A1 (enExample) |
| AU (1) | AU2004312411B8 (enExample) |
| BR (1) | BRPI0418317A (enExample) |
| CA (1) | CA2551877A1 (enExample) |
| EC (1) | ECSP066683A (enExample) |
| IL (1) | IL176494A0 (enExample) |
| MX (1) | MXPA06007514A (enExample) |
| NO (1) | NO20063478L (enExample) |
| NZ (1) | NZ547593A (enExample) |
| PE (1) | PE20051050A1 (enExample) |
| RU (1) | RU2422460C2 (enExample) |
| SG (1) | SG153874A1 (enExample) |
| TW (1) | TWI357906B (enExample) |
| UA (1) | UA93855C2 (enExample) |
| WO (1) | WO2005066204A2 (enExample) |
| ZA (1) | ZA200605227B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| US8426194B2 (en) * | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
| US8460864B2 (en) * | 2003-01-21 | 2013-06-11 | Ptc Therapeutics, Inc. | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same |
| AU2004312411B8 (en) * | 2003-12-31 | 2011-11-24 | Schering-Plough Pty. Limited | Neutralizing epitope-based growth enhancing vaccine |
| US20080118487A1 (en) * | 2004-09-30 | 2008-05-22 | Orico Limited | Myostatin Isoform |
| WO2006073827A2 (en) * | 2004-12-30 | 2006-07-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| ES2533464T3 (es) * | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anticuerpos anti-miostatina |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| AU2013231037B2 (en) * | 2006-08-03 | 2016-05-12 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| WO2008016314A1 (en) * | 2006-08-03 | 2008-02-07 | Orico Limited | Myostatin antagonists |
| KR101123531B1 (ko) * | 2006-09-05 | 2012-04-20 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| US8283115B1 (en) | 2007-06-20 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation |
| US8283116B1 (en) | 2007-06-22 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| TW201210612A (en) * | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
| KR20140005864A (ko) | 2010-08-16 | 2014-01-15 | 암젠 인코퍼레이티드 | 미오스타틴에 결합하는 항체, 조성물 및 방법 |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| SI2780368T1 (en) | 2011-11-14 | 2018-04-30 | Regeneron Pharmaceuticals, Inc. | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| AU2014262843B2 (en) | 2013-05-06 | 2017-06-22 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| HK1243940A1 (zh) * | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| IL255010B2 (en) | 2015-04-15 | 2024-01-01 | Regeneron Pharma | Methods of increasing strength and functionality with gdf8 inhibitors |
| SMT202500263T1 (it) * | 2015-09-15 | 2025-09-12 | Scholar Rock Inc | Anticorpi anti-pro-miostatina/miostatina latente e loro usi |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| KR102271635B1 (ko) | 2016-06-13 | 2021-07-06 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| DK3565592T5 (da) | 2017-01-06 | 2024-09-02 | Scholar Rock Inc | Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering |
| AU2019226551B2 (en) | 2018-03-01 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition |
| TW202430247A (zh) | 2022-12-22 | 2024-08-01 | 美商供石公司 | 肌肉生長抑制素活化之選擇性及強效抑制劑 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977438A (en) | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
| CA2014033C (en) | 1989-04-07 | 1993-02-09 | Stephen D. Acres | Compositions and treatments for pneumonia in animals |
| WO1993008290A1 (en) | 1991-10-16 | 1993-04-29 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
| US5422110A (en) | 1991-10-16 | 1995-06-06 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
| US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US6042832A (en) | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| AU746643B2 (en) | 1997-02-05 | 2002-05-02 | Metamorphix International, Inc. | Immunization against endogenous molecules |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| GB2333706A (en) * | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
| US6369201B1 (en) * | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| US6368597B1 (en) * | 1998-05-06 | 2002-04-09 | Matamorphix, Inc. | Methods of treating diabetes |
| US6284882B1 (en) | 1999-06-10 | 2001-09-04 | Abbott Laboratories | Myostatin gene promoter and inhibition of activation thereof |
| MXPA01013232A (es) * | 1999-07-20 | 2005-05-24 | Pharmexa As | Metodo para identificar la actividad de gdf-8. |
| ZA200003786B (en) | 1999-07-30 | 2002-01-21 | Pfizer Prod Inc | Myostatin regulatory region, nucleotide sequence determination and methods for its use. |
| WO2001026672A1 (en) | 1999-10-13 | 2001-04-19 | Roswell Park Memorial Institute | Induction of a strong immune response to a self-tumor associated antigen |
| US6730306B1 (en) | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
| US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| EP1572740A2 (en) | 2002-12-11 | 2005-09-14 | Pharmexa A/S | Targeting single epitopes |
| EA009056B1 (ru) | 2002-12-20 | 2007-10-26 | Амген, Инк. | Связывающие агенты, ингибирующие миостатин |
| AU2004312411B8 (en) * | 2003-12-31 | 2011-11-24 | Schering-Plough Pty. Limited | Neutralizing epitope-based growth enhancing vaccine |
| US20060281075A1 (en) * | 2004-12-22 | 2006-12-14 | Large Scale Biology Corporation | Purification of viruses, proteins and nucleic acids |
| WO2006073827A2 (en) | 2004-12-30 | 2006-07-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
-
2004
- 2004-12-21 AU AU2004312411A patent/AU2004312411B8/en not_active Ceased
- 2004-12-21 SG SG200904421-5A patent/SG153874A1/en unknown
- 2004-12-21 KR KR1020067013214A patent/KR20060120229A/ko not_active Abandoned
- 2004-12-21 NZ NZ547593A patent/NZ547593A/en not_active IP Right Cessation
- 2004-12-21 RU RU2006127314/10A patent/RU2422460C2/ru not_active IP Right Cessation
- 2004-12-21 BR BRPI0418317-7A patent/BRPI0418317A/pt not_active IP Right Cessation
- 2004-12-21 US US11/019,001 patent/US7371726B2/en not_active Expired - Fee Related
- 2004-12-21 WO PCT/US2004/043125 patent/WO2005066204A2/en not_active Ceased
- 2004-12-21 EP EP04815235A patent/EP1699820A2/en not_active Withdrawn
- 2004-12-21 CA CA002551877A patent/CA2551877A1/en not_active Abandoned
- 2004-12-21 UA UAA200608516A patent/UA93855C2/ru unknown
- 2004-12-21 CN CNA2004800395458A patent/CN1902221A/zh active Pending
- 2004-12-21 JP JP2006547309A patent/JP2007535912A/ja not_active Withdrawn
- 2004-12-21 MX MXPA06007514A patent/MXPA06007514A/es active IP Right Grant
- 2004-12-22 TW TW093140145A patent/TWI357906B/zh not_active IP Right Cessation
- 2004-12-22 AR ARP040104868A patent/AR047345A1/es active IP Right Grant
-
2005
- 2005-01-03 PE PE2005000029A patent/PE20051050A1/es not_active Application Discontinuation
-
2006
- 2006-06-22 IL IL176494A patent/IL176494A0/en unknown
- 2006-06-23 ZA ZA200605227A patent/ZA200605227B/xx unknown
- 2006-06-29 EC EC2006006683A patent/ECSP066683A/es unknown
- 2006-07-28 NO NO20063478A patent/NO20063478L/no not_active Application Discontinuation
-
2008
- 2008-04-02 US US12/061,012 patent/US7585648B2/en not_active Expired - Fee Related
-
2009
- 2009-08-04 US US12/535,298 patent/US7892561B2/en not_active Expired - Fee Related
-
2011
- 2011-01-20 JP JP2011010279A patent/JP2011083290A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006127314A (ru) | 2008-02-10 |
| US20050143306A1 (en) | 2005-06-30 |
| KR20060120229A (ko) | 2006-11-24 |
| JP2011083290A (ja) | 2011-04-28 |
| TWI357906B (en) | 2012-02-11 |
| AR047345A1 (es) | 2006-01-18 |
| US20090311282A1 (en) | 2009-12-17 |
| SG153874A1 (en) | 2009-07-29 |
| UA93855C2 (ru) | 2011-03-25 |
| CN1902221A (zh) | 2007-01-24 |
| US20080227156A1 (en) | 2008-09-18 |
| EP1699820A2 (en) | 2006-09-13 |
| NZ547593A (en) | 2009-09-25 |
| MXPA06007514A (es) | 2006-08-31 |
| BRPI0418317A (pt) | 2007-05-02 |
| ZA200605227B (en) | 2007-03-28 |
| AU2004312411A1 (en) | 2005-07-21 |
| PE20051050A1 (es) | 2005-12-12 |
| TW200526683A (en) | 2005-08-16 |
| AU2004312411B8 (en) | 2011-11-24 |
| RU2422460C2 (ru) | 2011-06-27 |
| WO2005066204A2 (en) | 2005-07-21 |
| NO20063478L (no) | 2006-08-28 |
| US7585648B2 (en) | 2009-09-08 |
| WO2005066204A3 (en) | 2005-08-11 |
| AU2004312411B2 (en) | 2011-11-03 |
| US7892561B2 (en) | 2011-02-22 |
| US7371726B2 (en) | 2008-05-13 |
| CA2551877A1 (en) | 2005-07-21 |
| IL176494A0 (en) | 2006-10-05 |
| JP2007535912A (ja) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066683A (es) | Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes | |
| CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
| CY1125429T1 (el) | Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| NO20023829D0 (no) | Proteosom influensavaksine | |
| CY1116506T1 (el) | Αντισωματα εναντι masp-2 | |
| DK1355930T3 (da) | Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen | |
| AR044985A1 (es) | Metodo y parche de inmunizacion por disposicion de microproyeccion | |
| CY1119650T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| ATE542829T1 (de) | Impfstoff | |
| MXPA05009580A (es) | Vacuna contra el virus de la influenza. | |
| BR122018016045B8 (pt) | proteína variante otimizada | |
| DE69939747D1 (de) | Verfahren von dna-impfung | |
| CY1117129T1 (el) | Συγκεκριμενες φωσφορικες ενωσεις αμυναλκιλικου γλυκοζαμινιδιου και η χρηση τους | |
| SI1644484T1 (sl) | Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah | |
| BRPI0519705A2 (pt) | composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
| ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
| EA200900738A1 (ru) | Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1 | |
| CY1118707T1 (el) | Her2 dna εμβολιο ως συμπληρωματικη αγωγη για καρκινους σε ζωα συντροφιας | |
| PE20060860A1 (es) | Vacuna basada en epitopes neutralizantes | |
| DE602004015141D1 (de) | Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe | |
| EP1578461A4 (en) | VACCINES AGAINST THE HIV TAT PROTEIN FOR GENERATING NEUTRALIZING ANTIBODIES | |
| AR020852A1 (es) | Antigenos de vacuna de leptospira para la prevencion de leptospirosis |